Astrazeneca

AZN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Value held

$22.5m

Combined value at quarter end

Last quarter

1 bought

3 sold or trimmed

Price at Q2 ’26 end

$189.15

-4.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-4.1%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

3Q1 ’26

4Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Astrazeneca.

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Download the holders: CSV · JSON · Markdown

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Astrazeneca
		Bought or sold				Filing
8 Aug 2026	Sharma ManiSee Remarks	▲ Bought	20.233	$160.57	$3k	Form 4